NCT06177522
Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer
Not Yet Recruiting · Phase 2 · Jinling Hospital, China · registry updated 2025-11-18
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
Clinical Study on the Safety and Efficacy of the efficacy and safety of Adebrelimab combined with chemotherapy for neoadjuvant treatment of resectable pancreatic cancer
Inclusion
- Age 18-80 years old, gender unlimited;
- Patients with resectable pancreatic adenocarcinoma confirmed by histopathology or cytology (CA19-9 \> 150 U/ml);
- No previous systemic treatment for pancreatic cancer;
- Measurable lesions defined by RECIST standard v1.1 (according to Recist 1.1 standard, the CT scan diameter of tumor lesions is ≥10 mm, and the scan layer thickness is not more than 5 mm);
- ECOG score: 0 \~ 1;
- Having adequate organ and bone marrow function, as defined below: Hemoglobin ≥9.0 g/dL neutrophil absolute count ≥1.5×109/L Platelet count ≥100×109/L INR≤1.5 Total bilirubin (TBL) ≤1.5× upper limit of normal (ULN) AST and ALT≤2.5×ULN Serum albumin ≥3.0 g/dL serum creatinine ≤1.5×ULN or measured creatinine clearance \> 60 mL/min or creatinine clearance \> 60 mL/min calculated according to the Cockcroft-Gault formula (using actual body weight) : Men: creatinine clearance =(weight x (140- age))/(72 x serum creatinine) Women: Creatinine clearance =(body weight x (140-age))/(72 x serum creatinine)x 0.85, where CL=mL/min; Serum creatinine =mg/dL;
Exclusion
- Concurrent with other uncured malignant tumors;
- Subjects who have previously used PD-1/PD-L1 antibodies;
- Subjects who can be surgically resected or treated with radical radiation;
- Subjects with a history of bleeding and any bleeding event with a severity rating of 3 or above on CTCAE4.0 within 4 weeks prior to screening;
- Urine routine indicated urinary protein ≥++ and confirmed 24-hour urinary protein quantity \> 1.0g;
- Subjects with poorly controlled hypertension;